irinotecan has been researched along with Sarcoma 180 in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, Y; Ding, J; Gao, H; Li, C; Lu, W; Pang, T; Shen, H; Sun, J; Xu, C; Zhang, X | 1 |
| Akagi, T; Higuchi, S; Inoue, K; Ishizaki, T; Kage, Y; Makinosumi, T; Ohdo, S; Taguchi, Y; Ushinohama, K; Yamauchi, A; Yukawa, E | 1 |
| Machida, Y; Onishi, H | 1 |
3 other study(ies) available for irinotecan and Sarcoma 180
| Article | Year |
|---|---|
Synthesis and antitumor activity of the hexacyclic camptothecin derivatives.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Cell Survival; Drug Screening Assays, Antitumor; Drug Stability; Enzyme Inhibitors; Humans; Mice; Sarcoma 180; Structure-Activity Relationship; Topoisomerase I Inhibitors | 2005 |
Cell kinetics-dependent antitumor effect of irinotecan hydrochloride induced by the synchronizing effect of hydroxyurea: cell kinetics and dosing time.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Body Weight; Bone Marrow Cells; Camptothecin; Cell Cycle; DNA; Esterases; Hydroxyurea; Irinotecan; Male; Mice; Mice, Inbred ICR; Neoplasm Transplantation; Sarcoma 180 | 2003 |
Antitumor properties of irinotecan-containing nanoparticles prepared using poly(DL-lactic acid) and poly(ethylene glycol)-block-poly(propylene glycol)-block-poly(ethylene glycol).
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Dosage Forms; Growth Inhibitors; Irinotecan; Lactates; Male; Mice; Microspheres; Nanotechnology; Polyethylene Glycols; Rats; Rats, Wistar; Sarcoma 180; Xenograft Model Antitumor Assays | 2003 |